Insulin efsitora alfa in type 2 diabetes: The evolution of basal insulin from daily to once-weekly formulations

Chair: Chantal Mathieu (BEL)

17:45 – 17:50Welcome and introductionChantal Mathieu (BEL)
17:50 – 18:00From guideline recommendations to clinical reality: Barriers to achieving treatment targets with basal insulin in type 2 diabetesAthena Philis-Tsimikas (USA)
18:00 – 18:10Insulin efsitora alfa in type 2 diabetes: Pharmacological properties for once weekly dosingHarpreet Bajaj (CAN)
18:10 – 18:30Insulin efsitora alfa in type 2 diabetes: Insights from the QWINT clinical trial programAll faculty
18:30 – 18:40Panel discussion and audience Q&A All faculty
18:40 – 18:45Closing remarks and take-home messages Chantal Mathieu (BEL)
Lilly logo
  • Wednesday, 30 September 2026
  • 17:45 - 18:45 CEST
  • Madrid Hall